Orexigen Therapeutics: Fighting Obesity

Obesity is a disease and is a health epidemic that is threatening the life of millions of people around the world. Obese people are more susceptible to having diabetes and heart problems. Several other critical illnesses are also linked to obesity.

Orexigen Therapeutics, Inc. is a biopharmaceutical company that focuses its resources in the creation of treatment for obesity. The company has been around since 2002 and was created by Eckard Weber. In 2014, their flagship product, the Contrave has been given approval to be marketed in the United States. By partnering with Takeda Pharmaceuticals, the company has penetrated the markets of Mexico and Canada and is now poised to penetrate the other international markets.

Orexigen is a publicly traded company on the NASDAQ. Its common stocks are marketed under the ticker symbol OREX. The business remains to be a component of the Russell 3000 Index and is headquartered in La Jolla, California.